Y-mAbs Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 57.27 | -100% | 19.75 | -100% |
| P/S |
|
3.82 | 33.44 | -88.58% |
|
|
| P/BV |
|
3.21 | 4.64 | -30.93% |
|
|
| P/FCF |
|
-9.02 | 42.53 | -121.21% |
|
|
| Ev/Ebitda |
|
-12.06 | -17.68 | -31.79% |
|
|
| Ev/S |
|
2.91 | 22.59 | -87.13% |
|
|
| Ev/FCF |
|
-9.06 | 47.55 | -119.05% |
|
|
| E/P |
|
-0.0872 | 0.0182 | -579.12% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-24.12 | -14.2 | 69.79% | -219.13 | -88.99% |
| ROE |
|
-21.22 | 9.78 | -316.89% |
|
|
| ROA |
|
-16.76 | 0.33 | -5177.13% |
|
|
| ROIC |
|
-55.2 | 7.63 | -823.05% |
|
|
| ROS |
|
-25.26 | -26.41 | -4.37% |
|
|
| ROCE |
|
-20.98 | 14.5 | -244.67% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.0694 | -3.87 | -98.21% | -0.0567 | +22.36% |
| Nеt Debt/Ebitda |
|
3.78 | -4.24 | -189.02% |
|
|
| Debt/Ratio |
|
0.0111 | 0.1853 | -94.01% |
|
|
| Debt/Equity |
|
0.0109 | 1.56 | -99.3% |
|
|
| Debt/Net Income |
|
-0.0662 | 10.06 | -100.66% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5351 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.235 | -100% |
|
|
| Average dividend growth |
|
0 | 1.41 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.486 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.64 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5351 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
307.78 | 30.62 | 905.16% | ||
| Growth impulse Ebitda in 5 years |
|
-69.96 | -17.42 | 301.61% | ||
| Growth impulse Net Income in 5 years |
|
-72.84 | -52.26 | 39.38% | ||
| Growth impulse FCF in 5 years |
|
-63.93 | -31.68 | 101.8% | ||
| Growth impulse EPS in 5 years |
|
-78.08 | -61.82 | 26.3% |
IP Score
3.05/10
